Reference Pricing
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
Affordable Care Act, Caught my eye, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 1/30/26
Read more: AMP is WAC — 1/30/26This week I had to remind myself that we live in the AND. Things can be truly awful around us, but there are still moments of happiness and hope. There are some periods in life where it is harder to find the AND, but it is there. At least that is what I have to…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Medicare Advantage, Pharmacy Benefit Managers, Reference PricingAMP is WAC — 1/22/26
Read more: AMP is WAC — 1/22/26I swear that inside I’m an 8-year-old at times (one that likes to make cocktails, but still), I am so excited about a snowstorm. Real snowfall! Cozy inside time interspersed with time shoveling out alongside neighbors. Watching the kids sled in front of the elementary school. Pulling out the snowshoes and remembering that they aren’t…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Orphan Drugs, Pharmacy Benefit Managers, Reference Pricing, ValueAMP is WAC — 1/16/26
Read more: AMP is WAC — 1/16/26In case you thought I’d leaving you hanging, today’s newsletter has a summary on GLOBE. Sphere it below? Calling it a Plan would be GENEROUS, but that’s a Whole Other Thing. On Thursday, the White House released a fact sheet urging Congress to enact President Trump’s “Great Healthcare Plan,” pitching it as a cost-cutting package…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Obesity, Reference PricingAMP is WAC — 1/9/26
Read more: AMP is WAC — 1/9/26Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year.…
-
GUARD Duty
Read more: GUARD DutyConfession. I was a bit of angry elf on Saturday morning. I was making dozens of cookies for neighbors and was just stressed and frustrated. Two proposed rules on a Friday afternoon are never fun, during the holiday season, brutal. My husband said that I had to be more in the moment. Try putting some…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Healthcare Costs, ICER, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 12/19/25
Read more: AMP is WAC — 12/19/25Today we’re expecting to hear more about manufacturer Most Favored Nation (MFN) agreements and (if you trust the rumors) maybe more about the MFN demos – the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model. I wasn’t planning on publishing the next two weeks,…
-
340B, Alzheimer’s, Caught my eye, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Preventative, Reference Pricing, ValueAMP is WAC — 12/12/25
Read more: AMP is WAC — 12/12/25Much of this week felt like playing catch-up from past weeks. Good timing because rumors are swirling about Most Favored Nation (MFN) demonstration releases for late next week. Comment letter fun during the holidays! For those of you who are new to these parts… welcome! I’m a health policy strategist focused on pharmaceuticals. My goal…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Home Health, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Preventative, Reference Pricing, TariffsAMP is WAC — 12/5/25
Read more: AMP is WAC — 12/5/25It is the kind of month where I walk around with a legal pad to capture all the random thoughts floating around my head. Which is how “figure out gift baking (scones? Levain cookies?)” ends up next to “Look at MedPAC agenda.” There are no dull moments around here. While I’m on the topic. MedPAC…
-
340B, Caught my eye, DTC, Medicaid, Medicare Negotiation, Medicare Part D, Reference Pricing, State-based ReformAMP is WAC — 10/10/25
Read more: AMP is WAC — 10/10/25Going crazy? Or is it just a party of one? This past month as been brutal. My house has been a parade of plumbers and HVAC and electricians. Plus, visits to orthopedists and veterinarians and car mechanics. If the universe is trying to say something, all I’m hearing is that I’m scoring a ton of…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)